Murray J. Tipping
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Murray J. Tipping has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Allan J. W. Lui
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5 shared publications - Charlene Kwong
Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. 8
5 shared publications - Christopher Antonio Febres-Aldana
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
5 shared publications - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
5 shared publications - Igor Odintsov
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
5 shared publications - Inna Khodos
Memorial Sloan Kettering Cancer Center 7 Anti-tumor Core Facility New York, New York
5 shared publications
Latest Publications
- Open Access
Microscale Characterization of Undecalcified Bone Tissue Using Correlative Atomic Force Microscopy and Histology
SUMMARY: Characterizing bone tissue in its mineralized state remains technically challenging. Conventional approaches typically compromise mechanical integrity through decalcification or lack the structural resolution necessary to capture microscale heterogeneity. Here we present an integrated workflow combining atomic force microscopy (AFM) with histological and immunofluorescence assays on adjacent undecalcified bone tissue cryosections. Using a tape-transfer mounting approach, we resolve mechanically and structurally distinct tissue types within a minimally processed single mouse femur section. Furthermore, we show that decalcification substantially alters nanoscale surface topography and local mechanical properties. Applied to an aging cohort of C57BL/6J female mice spanning 7 to 115 weeks, the proposed method detects age-associated changes in bone matrix structure and stiffness. The approach provides a practical methodology for spatially correlating nanomechanical properties with molecular markers in bone and other mineralized tissues, with broad applicability to disease models including cancer metastasis, osteoporosis, and osteoarthritis.
Open AccessMicroscale Characterization of Undecalcified Bone Tissue Using Correlative Atomic Force Microscopy and Histology
SUMMARY: Characterizing bone tissue in its mineralized state remains technically challenging. Conventional approaches typically compromise mechanical integrity through decalcification or lack the structural resolution necessary to capture microscale heterogeneity. Here we present an integrated workflow combining atomic force microscopy (AFM) with histological and immunofluorescence assays on adjacent undecalcified bone tissue cryosections. Using a tape-transfer mounting approach, we resolve mechanically and structurally distinct tissue types within a minimally processed single mouse femur section. Furthermore, we show that decalcification substantially alters nanoscale surface topography and local mechanical properties. Applied to an aging cohort of C57BL/6J female mice spanning 7 to 115 weeks, the proposed method detects age-associated changes in bone matrix structure and stiffness. The approach provides a practical methodology for spatially correlating nanomechanical properties with molecular markers in bone and other mineralized tissues, with broad applicability to disease models including cancer metastasis, osteoporosis, and osteoarthritis.
- Open Access
- 25 March 2025
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (6) , e202403126
Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors
Upon spinal cord injury, axons attempting to regenerate need to overcome the repulsive actions of myelin-associated inhibitors, including the myelin-associated glycoprotein, Nogo-A, and the oligodendrocyte myelin glycoprotein. These inhibitors bind and signal through a neuronal receptor/co-receptor/transducer complex composed of NgR1, Lingo-1, and p75. Consequently, p75 is cleaved by alpha secretase followed by gamma-secretase, triggering downstream signaling that inhibits axonal regrowth. ADAM10 and ADAM17 are both known to function as alpha secretases in neurons. Here we show that ADAM17, and not ADAM10, is the alpha secretase that recognizes and cleaves p75, when it is a part of a 5-component neuron-myelin signaling complex comprising NgR1, Lingo-1, p75, GT1b, and a myelin inhibitor. Importantly, we demonstrate the ability of inhibitory anti-ADAM17 mAbs to abrogate the cleavage of p75 in a neuroblastoma-glioma cell line and reverse the neurite outgrowth inhibition by myelin-associated inhibitors.
- 25 March 2025
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (6) , e202403126
Open AccessAntibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors
Upon spinal cord injury, axons attempting to regenerate need to overcome the repulsive actions of myelin-associated inhibitors, including the myelin-associated glycoprotein, Nogo-A, and the oligodendrocyte myelin glycoprotein. These inhibitors bind and signal through a neuronal receptor/co-receptor/transducer complex composed of NgR1, Lingo-1, and p75. Consequently, p75 is cleaved by alpha secretase followed by gamma-secretase, triggering downstream signaling that inhibits axonal regrowth. ADAM10 and ADAM17 are both known to function as alpha secretases in neurons. Here we show that ADAM17, and not ADAM10, is the alpha secretase that recognizes and cleaves p75, when it is a part of a 5-component neuron-myelin signaling complex comprising NgR1, Lingo-1, p75, GT1b, and a myelin inhibitor. Importantly, we demonstrate the ability of inhibitory anti-ADAM17 mAbs to abrogate the cleavage of p75 in a neuroblastoma-glioma cell line and reverse the neurite outgrowth inhibition by myelin-associated inhibitors.
- Open Access
- 2 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Invasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2
Glioblastoma (GBM) is a malignant brain tumor with diffuse infiltration. Here, we demonstrate how GBM cells usurp guidance receptor Plexin-B2 for confined migration through restricted space. Using live-cell imaging to track GBM cells negotiating microchannels, we reveal endocytic vesicle accumulation at cell front and filamentous actin assembly at cell rear in a polarized manner. These processes are interconnected and require Plexin-B2 signaling. We further show that Plexin-B2 governs membrane tension and other membrane features such as endocytosis, phospholipid composition, and inner leaflet surface charge, thus providing biophysical mechanisms by which Plexin-B2 promotes GBM invasion. Together, our studies unveil how GBM cells regulate membrane tension and mechano-electrical coupling to adapt to physical constraints and achieve polarized confined migration.
- 2 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessInvasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2
Glioblastoma (GBM) is a malignant brain tumor with diffuse infiltration. Here, we demonstrate how GBM cells usurp guidance receptor Plexin-B2 for confined migration through restricted space. Using live-cell imaging to track GBM cells negotiating microchannels, we reveal endocytic vesicle accumulation at cell front and filamentous actin assembly at cell rear in a polarized manner. These processes are interconnected and require Plexin-B2 signaling. We further show that Plexin-B2 governs membrane tension and other membrane features such as endocytosis, phospholipid composition, and inner leaflet surface charge, thus providing biophysical mechanisms by which Plexin-B2 promotes GBM invasion. Together, our studies unveil how GBM cells regulate membrane tension and mechano-electrical coupling to adapt to physical constraints and achieve polarized confined migration.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Data from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose:Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target.Experimental Design:ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays.Results:ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status.Conclusions:ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose:Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target.Experimental Design:ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays.Results:ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status.Conclusions:ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S2 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Supplementary Table S1 from HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
- Top Cited Papers
- 9 August 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (20) , 4701-4713
HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target. Experimental Design: ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays. Results: ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status. Conclusions: ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- 9 August 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (20) , 4701-4713
Top Cited PapersHER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive soft tissue sarcoma that arises in the abdominopelvic cavity of young males. Since the discovery of EWSR1::WT1 fusion as the driver of DSRCT, no actionable genomic alterations have been identified, limiting disease management to a combination of surgery, chemotherapy, and radiation, with very poor outcomes. Herein, we evaluated ERBB2/HER2 expression in DSRCT as a therapeutic target. Experimental Design: ERBB2/HER2 expression was assessed in clinical samples and patient-derived xenografts (PDX) using RNA sequencing, RT-qPCR, and a newly developed HER2 IHC assay (clone 29D8). Responses to HER2 antibody–drug conjugates (ADC)—trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine—were evaluated in DSRCT PDX, cell line, and organoid models. Drug internalization was demonstrated by live microscopy. Apoptosis was evaluated by Western blotting and caspase activity assays. Results: ERBB2/HER2 was detectable in DSRCT samples from patients and PDXs, with higher sensitivity RNA assays and improved IHC detectability using clone 29D8. Treatment of ERBB2/HER2-expressing DSRCT PDX, cell line, and organoid models with T-DXd or trastuzumab emtansine resulted in tumor regression. This therapeutic response was long-lasting in T-DXd–treated xenografts and was mediated by rapid HER2 ADC complex internalization and cytotoxicity, triggering p53-mediated apoptosis and growth arrest. Xenograft regression was associated with bystander payload effects triggering global tumor niche responses proportional to HER2 status. Conclusions: ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
- 7 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (96) , eadl2388
Plasma membrane abundance dictates phagocytic capacity and functional cross-talk in myeloid cells
Professional phagocytes like neutrophils and macrophages tightly control what they consume, how much they consume, and when they move after cargo uptake. We show that plasma membrane abundance is a key arbiter of these cellular behaviors. Neutrophils and macrophages lacking the G protein subunit Gβ 4 exhibited profound plasma membrane expansion, accompanied by marked reduction in plasma membrane tension. These biophysical changes promoted the phagocytosis of bacteria, fungus, apoptotic corpses, and cancer cells. We also found that Gβ 4 -deficient neutrophils are defective in the normal inhibition of migration following cargo uptake. Sphingolipid synthesis played a central role in these phenotypes by driving plasma membrane accumulation in cells lacking Gβ 4 . In Gβ 4 knockout mice, neutrophils not only exhibited enhanced phagocytosis of inhaled fungal conidia in the lung but also increased trafficking of engulfed pathogens to other organs. Together, these results reveal an unexpected, biophysical control mechanism central to myeloid functional decision-making.
- 7 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (96) , eadl2388
Plasma membrane abundance dictates phagocytic capacity and functional cross-talk in myeloid cells
Professional phagocytes like neutrophils and macrophages tightly control what they consume, how much they consume, and when they move after cargo uptake. We show that plasma membrane abundance is a key arbiter of these cellular behaviors. Neutrophils and macrophages lacking the G protein subunit Gβ 4 exhibited profound plasma membrane expansion, accompanied by marked reduction in plasma membrane tension. These biophysical changes promoted the phagocytosis of bacteria, fungus, apoptotic corpses, and cancer cells. We also found that Gβ 4 -deficient neutrophils are defective in the normal inhibition of migration following cargo uptake. Sphingolipid synthesis played a central role in these phenotypes by driving plasma membrane accumulation in cells lacking Gβ 4 . In Gβ 4 knockout mice, neutrophils not only exhibited enhanced phagocytosis of inhaled fungal conidia in the lung but also increased trafficking of engulfed pathogens to other organs. Together, these results reveal an unexpected, biophysical control mechanism central to myeloid functional decision-making.
- Open Access
Invasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2
Glioblastoma (GBM) is a malignant brain tumor with uncontrolled invasive growth. Here, we demonstrate how GBM cells usurp guidance receptor Plexin-B2 to gain biomechanical plasticity for polarized migration through confined space. Using live-cell imaging to track GBM cells negotiating microchannels, we reveal active endocytosis at cell front and filamentous actin assembly at rear to propel GBM cells through constrictions. These two processes are interconnected and governed by Plexin-B2 that orchestrates cortical actin and membrane tension, shown by biomechanical assays. Molecular dynamics simulations predict that balanced membrane and actin tension are required for optimal migratory velocity and consistency. Furthermore, Plexin-B2 mechanosensitive function requires a bendable extracellular ring structure and affects membrane internalization, permeability, phospholipid composition, as well as inner membrane surface charge. Together, our studies unveil a key element of membrane tension and mechanoelectrical coupling via Plexin-B2 that enables GBM cells to adapt to physical constraints and achieve polarized confined migration.
Open AccessInvasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2
Glioblastoma (GBM) is a malignant brain tumor with uncontrolled invasive growth. Here, we demonstrate how GBM cells usurp guidance receptor Plexin-B2 to gain biomechanical plasticity for polarized migration through confined space. Using live-cell imaging to track GBM cells negotiating microchannels, we reveal active endocytosis at cell front and filamentous actin assembly at rear to propel GBM cells through constrictions. These two processes are interconnected and governed by Plexin-B2 that orchestrates cortical actin and membrane tension, shown by biomechanical assays. Molecular dynamics simulations predict that balanced membrane and actin tension are required for optimal migratory velocity and consistency. Furthermore, Plexin-B2 mechanosensitive function requires a bendable extracellular ring structure and affects membrane internalization, permeability, phospholipid composition, as well as inner membrane surface charge. Together, our studies unveil a key element of membrane tension and mechanoelectrical coupling via Plexin-B2 that enables GBM cells to adapt to physical constraints and achieve polarized confined migration.